Aclaris Therapeutics Beheer
Beheer criteriumcontroles 4/4
De CEO Aclaris Therapeutics is Neal Walker, benoemd in Jul2012, heeft een ambtstermijn van 12.33 jaar. bezit rechtstreeks 1.92% van de aandelen van het bedrijf, ter waarde $ 2.86M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.4 jaar en 10.5 jaar.
Belangrijke informatie
Neal Walker
Algemeen directeur
US$73.5k
Totale compensatie
| Percentage CEO-salaris | n/a |
| Dienstverband CEO | 12.3yrs |
| Eigendom CEO | 1.9% |
| Management gemiddelde ambtstermijn | 2.4yrs |
| Gemiddelde ambtstermijn bestuur | 10.5yrs |
Recente managementupdates
Recent updates
Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?
Aug 08
We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
May 03Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up
Mar 07Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report
Mar 01Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 19Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week
Nov 11Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Nov 03Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results
Aug 10What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today
Aug 08Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Jun 06We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely
Apr 07Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Dec 21Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions
Oct 06Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Aug 26Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata
Aug 25Aclaris Therapeutics gets a new COO
Aug 01Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth
May 28We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
Dec 14Is Aclaris Therapeutics (NASDAQ:ACRS) Using Too Much Debt?
Aug 25Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$59m |
| Mar 31 2024 | n/a | n/a | -US$77m |
| Dec 31 2023 | US$74k | n/a | -US$88m |
| Sep 30 2023 | n/a | n/a | -US$115m |
| Jun 30 2023 | n/a | n/a | -US$105m |
| Mar 31 2023 | n/a | n/a | -US$96m |
| Dec 31 2022 | US$6m | US$590k | -US$87m |
| Sep 30 2022 | n/a | n/a | -US$82m |
| Jun 30 2022 | n/a | n/a | -US$83m |
| Mar 31 2022 | n/a | n/a | -US$81m |
| Dec 31 2021 | US$7m | US$567k | -US$91m |
| Sep 30 2021 | n/a | n/a | -US$82m |
| Jun 30 2021 | n/a | n/a | -US$71m |
| Mar 31 2021 | n/a | n/a | -US$65m |
| Dec 31 2020 | US$2m | US$424k | -US$51m |
| Sep 30 2020 | n/a | n/a | -US$57m |
| Jun 30 2020 | n/a | n/a | -US$69m |
| Mar 31 2020 | n/a | n/a | -US$102m |
| Dec 31 2019 | US$3m | US$500k | -US$114m |
| Sep 30 2019 | n/a | n/a | -US$118m |
| Jun 30 2019 | n/a | n/a | -US$115m |
| Mar 31 2019 | n/a | n/a | -US$79m |
| Dec 31 2018 | US$4m | US$550k | -US$82m |
| Sep 30 2018 | n/a | n/a | -US$81m |
| Jun 30 2018 | n/a | n/a | -US$79m |
| Mar 31 2018 | n/a | n/a | -US$86m |
| Dec 31 2017 | US$810k | US$510k | -US$50m |
Compensatie versus markt: De totale vergoeding ($USD 73.50K ) Neal } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 655.65K ).
Compensatie versus inkomsten: De vergoeding van Neal is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Neal Walker (54 yo)
12.3yrs
Tenure
US$73,500
Compensatie
Dr. Neal S. Walker, D.O. & M.D., is Venture Partner of Forge Life Science Partners. He Co-founded Aclaris Therapeutics, Inc. in 2012 and has been its Director since July 2012 and serves as its Chairman sin...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 12.3yrs | US$73.50k | 1.92% $ 2.9m | |
| Chief Financial Officer | 1.8yrs | US$2.34m | 0.035% $ 51.6k | |
| Chief Scientific Officer | 3.8yrs | US$2.26m | 0.26% $ 390.8k | |
| Chief Business Officer | 2.8yrs | US$2.33m | 0.048% $ 71.1k | |
| General Counsel & Corporate Secretary | 2.4yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Chemistry | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Project Leadership | less than a year | geen gegevens | geen gegevens | |
| Senior Vice President of Clinical Development | less than a year | geen gegevens | geen gegevens |
2.4yrs
Gemiddelde duur
56.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ACRS wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.4 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 12.3yrs | US$73.50k | 1.92% $ 2.9m | |
| Independent Director | 4.8yrs | US$180.38k | 0.018% $ 26.2k | |
| Member of Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 10.2yrs | US$194.38k | 0.061% $ 90.6k | |
| Member of Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Advisory Board | no data | geen gegevens | geen gegevens | |
| Lead Independent Director | 10.8yrs | US$206.88k | 0.075% $ 111.1k | |
| Member of Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Advisory Board | no data | geen gegevens | geen gegevens |
10.5yrs
Gemiddelde duur
60yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ACRS zijn ervaren en ervaren (gemiddelde ambtstermijn van 10.5 jaar).